Add to ORKGThe effects of somatostatin, or somatotropin release-inhibiting factor (SRIF), and SRIF analogs in human diseases have been widely investigated to potentially expand the therapeutic applications of commercially available and newly designed compounds belonging to this class of agents. Several preclinical studies and clinical trials have demonstrated the antiproliferative and antisecretory effects of SRIF and its analogs. This review discusses results from studies investigating the secretory activity and cell viability of SRIF analogs, and the potential of new therapeutic applications of these drugs in endocrine diseases and, in particular, as a treatment for endocrine neoplasia
textabstractSomatostatin receptors expressed on tumor cells form the rationale for somatostati...
The evidence that prostate cancer (PCa) expresses specific receptors for hormones and neuropeptides,...
Neuroendocrine tumours (NETs) represent a heterogeneous family of neoplasms, which may develop from ...
Somatostatin has been discovered as a somatotroph release inhibitory factor (SRIF), and, indeed, it ...
International audienceSince its discovery three decades ago as an inhibitor of GH release from the p...
The antisecretory effects of somatostatin (SRIF) and its analogs are widely recognised and provide t...
The pharmacological effects (i.e., inhibition of endocrine secretion and cell proliferation) mediate...
Over the past decade, impressive antineoplastic activity of somatostatin analogs has been demonstrat...
Somatostatin analogs (SSAs) have an important role in the management of patients with neuroendocrine...
Somatostatin analogs (SSAs) have an important role in the management of patients with neuroendocrine...
Somatostatin is an endogeneous cyclic tetradecapeptide hormone that exerts multiple biological activ...
Somatostatin is a neuropeptide produced by paracrine cells that are located throughout the gastroint...
Existing treatments for breast cancer are helpful for many patients, but treatment failure remains a...
Somatostatin (SRIF) analogs interacting with SRIF receptor (SSTR) subtypes SSTR2 and SSTR5 reduce ho...
Somatostatin blocks the release of numerous growth factors and is therefore a potent inhibitor of ce...
textabstractSomatostatin receptors expressed on tumor cells form the rationale for somatostati...
The evidence that prostate cancer (PCa) expresses specific receptors for hormones and neuropeptides,...
Neuroendocrine tumours (NETs) represent a heterogeneous family of neoplasms, which may develop from ...
Somatostatin has been discovered as a somatotroph release inhibitory factor (SRIF), and, indeed, it ...
International audienceSince its discovery three decades ago as an inhibitor of GH release from the p...
The antisecretory effects of somatostatin (SRIF) and its analogs are widely recognised and provide t...
The pharmacological effects (i.e., inhibition of endocrine secretion and cell proliferation) mediate...
Over the past decade, impressive antineoplastic activity of somatostatin analogs has been demonstrat...
Somatostatin analogs (SSAs) have an important role in the management of patients with neuroendocrine...
Somatostatin analogs (SSAs) have an important role in the management of patients with neuroendocrine...
Somatostatin is an endogeneous cyclic tetradecapeptide hormone that exerts multiple biological activ...
Somatostatin is a neuropeptide produced by paracrine cells that are located throughout the gastroint...
Existing treatments for breast cancer are helpful for many patients, but treatment failure remains a...
Somatostatin (SRIF) analogs interacting with SRIF receptor (SSTR) subtypes SSTR2 and SSTR5 reduce ho...
Somatostatin blocks the release of numerous growth factors and is therefore a potent inhibitor of ce...
textabstractSomatostatin receptors expressed on tumor cells form the rationale for somatostati...
The evidence that prostate cancer (PCa) expresses specific receptors for hormones and neuropeptides,...
Neuroendocrine tumours (NETs) represent a heterogeneous family of neoplasms, which may develop from ...